SHERIDAN, WYOMING – July 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) has confirmed the exchange ratio for its 2024 dividend, announcing a share-based conversion rate of one new common share for every 23.6353 existing shares. The ratio was determined based on the volume-weighted average price of Philips shares traded on Euronext Amsterdam across May 30, June 2, and June 3, 2025, which stood at EUR 20.0600.
SHERIDAN, WYOMING – July 25, 2025 – Royal Philips has initiated a major international clinical trial to evaluate its new ultra-low X-ray dose technology designed for coronary procedures. The RADIQAL trial aims to generate real-world evidence that the innovation can significantly reduce radiation exposure for both patients and clinical staff without compromising the image quality or procedural performance critical to interventional cardiology.
Strategic push for radiation dose reduction in cardiology
SHERIDAN, WYOMING – July 25, 2025 – In a significant move reshaping national vaccine policy, the U.S. Department of Health and Human Services (HHS) has announced it will eliminate thimerosal from all influenza vaccines distributed in the United States. The decision follows a unanimous vote by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) on June 26, 2025, and marks the end of an era for a preservative that has been both a practical necessity and a source of public debate for over two decades.
SHERIDAN, WYOMING – July 25, 2025 – Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx). The application sought approval for this regimen as a second-line treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
SHERIDAN, WYOMING – July 25, 2025 – Genentech has confirmed another round of workforce reductions at its South San Francisco headquarters, cutting 87 jobs effective September 15, 2025. The move comes as part of a broader, ongoing strategy to recalibrate operations and align resources with evolving scientific and business priorities.
SHERIDAN, WYOMING – July 25, 2025 – AbbVie and ADARx Pharmaceuticals have announced a major strategic collaboration and license option agreement to co-develop next-generation small interfering RNA (siRNA) therapeutics, targeting several high-impact disease areas including neuroscience, immunology and oncology.
SHERIDAN, WYOMING – July 25, 2025 – ADARx Pharmaceuticals is making waves in the RNA therapeutics landscape under the leadership of CEO Zhen Li, who has emerged as a key figure in advancing siRNA technologies with precision, partnership, and purpose. With a $200 million Series C financing round completed and a major strategic licensing deal secured with AbbVie, ADARx is expanding its pipeline while positioning itself for long-term commercial impact.
Forging a Leadership Path from Chemistry to Commercialization
SHERIDAN, WYOMING – July 25, 2025 – AstraZeneca has reported positive topline results from its Phase III PREVAIL trial evaluating gefurulimab, a complement C5-inhibiting nanobody, for the treatment of generalized myasthenia gravis (gMG). The investigational therapy met all primary and secondary endpoints, signaling a potential new contender in the highly competitive $20 billion gMG market.
Phase III Results Suggest Clinical Significance
SHERIDAN, WYOMING – July 25, 2025 – Novartis AG has entered a strategic drug discovery alliance with Matchpoint Therapeutics, securing global rights to novel oral inhibitors aimed at treating multiple inflammatory conditions. The deal underscores Novartis' commitment to expanding its pipeline through innovation-driven partnerships and bolsters its focus on next-generation therapeutic platforms.
Strategic investment in covalent chemistry
SHERIDAN, WYOMING – July 25, 2025 – As Q2 2025 earnings season unfolds, leading biotech firms face scrutiny amid a backdrop of regulatory headwinds, clinical trial disruptions, and evolving commercial strategies. Several key players are poised to reveal performance metrics that could reshape market sentiment across the pharmaceutical innovation landscape.
Sarepta Faces Scrutiny Amid Safety Setbacks and Strategic Pivot